Reducing the bioavailability of VEGF with full-length IgG antibodies compromises not only the tumor vasculature, but also the frequency and phenotype of immune infiltrative cells in tumors, changing the local ecosystem. The gene discussed is VEGFA; the disease is neoplasm.